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Transient Anti-CD40L Co-Stimulation Blockade
Prevents Immune Responses against Human Bullous
Pemphigoid Antigen 2: Implications for Gene
Therapy
Christoph M. Lanschuetzer1, Edit B. Olasz1, Zelmira Lazarova1 and Kim B. Yancey1
Skin grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basement
membrane elicit hBPAG2-specific IgG and graft loss in wild-type (Wt) recipients. Graft loss was dependent on
CD4þ T cells and correlated with the production and tissue deposition of hBPAG2-specific IgG. To explore the
role of CD40/CD40 ligand (CD40L) interaction in this model, Wt mice grafted with transgenic (Tg) skin were
treated with hamster anti-CD40L mAb MR1. In contrast to grafted Wt mice treated with equivalent doses of
control IgG, 22 of 23 MR1-treated Wt mice did not develop hBPAG2-specific IgG or graft loss forX60 days. MR1-
treated mice also accepted a second Tg skin graft without durable production of hBPAG2-specific IgG or graft
loss. Moreover, splenocytes and enriched CD4þ T cells from MR1-treated graft recipients transferred un- or
hyporesponsiveness to hBPAG2 to other mice and demonstrated a dominant tolerant effect over cotransferred
naive splenocytes following adoptive transfer to Rag2/ mice. Successful inhibition of hBPAG2-specific IgG
production and Tg graft loss following CD40:CD40L co-stimulatory blockade in this model provides
opportunities to study mechanisms of peripheral tolerance and generate antigen-specific regulatory CD4þ
cells—issues of relevance to patients with pemphigoid as well as individuals undergoing gene replacement
therapy for epidermolyis bullosa.
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INTRODUCTION
To study experimental immune responses against human
bullous pemphigoid antigen 2 (hBPAG2) (Van den Bergh and
Giudice, 2003; Franzke et al., 2005), our laboratory recently
developed C57BL/6 transgenic (Tg) mice expressing hBPAG2
in murine epidermal basement membrane (BM). Full thick-
ness grafts of hBPAG2 Tg skin placed on the flanks of gender-
matched, syngeneic wild-type (Wt) mice consistently elicited
prompt (detectable within 16±2 days), robust (titer X1280),
and durable (present 4270 days) IgG that bound (1) human
epidermal BM, (2) BPAG2 extracted from human keratino-
cytes, and (3) the NC16A domain of hBPAG2. In vivo
deposits of IgG in epidermal BMs of grafts prompted
complement activation, neutrophil-rich leukocytic infiltrates,
subepidermal blister formation, and loss of Tg skin grafts
within 28–30 days. Major histocompatibility class II/ mice
grafted with Tg skin developed neither specific IgG nor graft
loss, indicating that major histocompatibility class II:CD4þ
T-cell interactions are crucial for these responses and that
CD8þ T cells do not mediate graft loss in this model (Olasz
et al., 2007). These studies have direct relevance to patients
with the pemphigoid group of autoimmune blistering diseases
as well as individuals with generalized atrophic benign
epidermolysis bullosa (OMIM 226650), (Hintner and Wolff,
1982; Darling et al., 1997; Bauer and Lanschuetzer, 2003)
who are at risk of developing unwanted immune responses to
hBPAG2 as a consequence of successful gene therapy
(Khavari, 1998; Dellambra et al., 2000; Ohyama et al.,
2003; Chen and Woodley, 2006; Mavilio et al., 2006;
Woodley et al., 2007). The consistent experimental responses
seen in Wt mice grafted with Tg skin indicate that this animal
model has utility for the study of interventions that may block,
attenuate, and/or silence the production of IgG directed
against hBPAG2 in epidermal BM. Given the central role that
CD40:CD40 ligand (CD40L) interactions play in T-cell-
dependent humoral immune responses, we sought to
determine if blockade of CD40L by mAb MR1 could impair
the development (or attenuate the titer) of anti-hBPAG2 IgG
in Wt mice bearing Tg skin grafts (Noelle et al., 1992; Roy
et al., 1993).
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RESULTS
CD40L engagement is necessary for anti-BM IgG production
following hBPAG2 Tg skin graft placement
Wt mice (n¼4) grafted with gender-matched, syngeneic
hBPAG2 Tg skin developed IgG that bound human epidermal
BM with high and durable titers within 17 days (specifically,
titers¼640–5120 vs the epidermal side of 1 M NaCl split skin
Xday 17 after grafting (observation period, 90 days)).
Conversely, CD40L/ mice (n¼4) grafted with Tg skin
did not develop anti-BM IgG. Moreover, although Wt
recipients lost Tg skin grafts within 28–30 days, CD40L/
mice retained Tg skin grafts for their entire period of study
(that is, 235 days). These studies showed that CD40:CD40L
interactions are crucial for generation of anti-hBPAG2 IgG in
this animal model and that blockade of this interplay may
impair or avert such humoral immune responses.
Transient co-stimulatory blockade with anti-murine CD40L
mAb (MR1) prevented anti-BM IgG production and hBPAG2 Tg
skin graft loss in Wt mice
To assess the effect of CD40:CD40L blockade in this animal
model, Wt mice (n¼23) were grafted with Tg skin and
treated with MR1 as described. Sera from 22 of 23 mice
showed no evidence of IgG reactive with human epidermal
BM for X60 days following graft placement (Figure 1a). Tg
skin grafts placed on MR1-treated Wt mice remained viable
and intact for as long as 60–305 days (that is, their entire
period of study). Interestingly, the one mouse in this series
that developed anti-BM IgG showed graft loss within 10 days
of becoming seropositive on day 30. Conversely, Wt mice
grafted with Tg skin and treated with equivalent amounts of
hamster IgG (hIgG; controls, n¼14) developed IgG that
bound human epidermal BM (Figure 1a). All controls
developed anti-BM IgG with kinetics and titers such as those
seen in untreated Wt mice grafted with Tg skin. Nine of
fourteen hIgG-treated controls lost Tg grafts within 30 days
such as untreated Wt graft recipients; for unknown reasons,
five controls showed a delay in the involution and/or loss of
Tg skin grafts. Immunoblot studies showed that sera from
three representative controls contained IgG that bound
hBPAG2 in human keratinocyte extracts as well as a bacterial
recombinant corresponding to the NC16A immunodominant
portion of this protein (Figure 1b and c, respectively).
Conversely, sera from five representative MR1-treated mice
showed no evidence of IgG reactive with hBPAG2 or NC16A
by immunoblot (Figure 1b and c, respectively).
Transient anti-CD40L blockade did not diminish serum IgM and
IgG levels
To determine if MR1 administration selectively blocked
elicitation of anti-hBPAG2 IgG or caused an overall reduction
in serum Ig levels, IgG and IgM in the sera of mice treated
with either MR1 (n¼8) or control hIgG (n¼ 2) were
quantitated at various time points within 60 days of graft
placement. These studies found no reductions in levels of IgG
and IgM at any time point in experimental subjects or
controls. These findings are in accord with earlier studies
showing that anti-CD40L antibody treatment does not elicit
generalized immunosuppression in mice (Durie et al., 1993;
Mohan et al., 1995; Early et al., 1996; Gerritse et al., 1996).
MR1 treatment did not affect established anti-human BM
antibody titers in grafted Wt mice
To investigate the effect of MR1 treatment on an established
and robust hBPAG2-specific humoral immune response, two
seropositive Wt mice previously grafted with Tg skin (that is,
immune Wt mice) were treated with 1mg of MR1 on day 20
post-grafting and with 0.5mg of MR1 on days 22, 24, 27, and
34. As shown in Figure 2, administration of MR1 to immune
Wt mice did not diminish existing levels of anti-BM IgG.
CD40L blockade rendered Wt mice hypo- or nonresponsive to a
second Tg skin graft
To assess further, the long-term nonresponsiveness of MR1-
treated mice to Tg skin, sequential graft experiments were
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Figure 1. Transient CD40L blockade prevented anti-BM IgG production and
loss of Tg skin grafts on Wt mice. (a) Anti-BM IgG and graft loss did not develop
in 22 of 23 MR1-treated Wt mice grafted with hBPAG2 Tg skin. Interestingly, the
one mouse in this series that developed anti-BM IgG (day 30, *) lost its graft within
20 days of the appearance of this specific antibody. In contrast, Wt mice grafted
with Tg skin and treated with equivalent amounts of control hamster IgG
developed anti-BM IgG with titers, kinetics, and durations equivalent to those
seen in untreated Wt mice grafted with Tg skin. Immunoblot studies of human
keratinocyte extracts (b) and a bacterial recombinant corresponding to the NC16A
immunodominant portion of hBPAG2 (c) show that sera from three representative
controls treated with hamster IgG contained IgG reactive with hBPAG2 as well as
NC16A, whereas no such IgG was found in sera from five representative MR1-
treated mice (all samples obtained 60 days after graft placement). Positive controls
in these studies included sera from patients with bullous pemphigoid (BP1 and
BP2) and a murine mAb specific for NC16A (HD-18); negative controls included
normal human serum (NHS) and normal mouse serum (NMS).
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performed in seronegative Wt mice (n¼5) that had retained
an initial Tg skin graft for 60 days (a time point when MR1
concentrations in the circulation were greatly diminished
(calculated half-life of MR1 in C57BL/6 mice¼10.4 days;
Pearson et al., 2003). Two of five mice in this series did not
develop anti-BM IgG after placement of a second Tg skin
graft. Of three mice that seroconverted following placement
of a second Tg skin graft, all showed diminished, delayed, or
transient titers of specific IgG in contrast to high titers of
specific IgG seen in controls initially treated with hIgG and
subjected to a second Tg skin graft on day 60 (Table 1).
Moreover, all five MR1-treated mice accepted both the initial
and the second Tg skin grafts for the full observation period
(that is, 300 days).
Lymphocytes from MR1-treated mice prevented or diminished
anti-BM IgG production by naive lymphocytes following
cotransfer to Rag2/ mice
To determine if lymphocytes from MR1-treated mice had a
‘‘dominant’’ or ‘‘infectious’’ (Qin et al., 1993) tolerogenic
effect over lymphocytes from naive Wt mice, a series of
adoptive transfer studies were performed. Initial studies
showed that adoptive transfer of 2107 lymphocytes from
naive Wt mice to Rag2/ mice endowed the latter (n¼ 5)
with the ability to develop high and durable titers of anti-BM
IgG following placement of hBPAG2 Tg skin grafts (Figure
3a). Moreover, Tg skin grafts on such seropositive Rag2/
mice involuted and disappeared within 30–55 days. Thus,
‘‘reconstituted’’ Rag2/mice grafted with Tg skin were able
to generate hBPAG2-specific IgG and lose grafts such as Wt
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Figure 2. Administration of MR1 to immune Wt mice did not diminish
existing levels of anti-BM IgG. Administration of MR1mAb (total doses
equivalent to those used in experiments shown in Figure 2) administered
20–34 days after placement of Tg skin grafts did not abrogate established titers
of anti-BM IgG (n¼2; triangles represent kinetics of anti-BM IgG titers in two
separate mice).
Table 1. CD40L blockade rendered Wt mice hypo- or
nonresponsive to a second Tg skin graft
Titers of anti-BM IgG in MR1-treated mice
Days (d) after first graft Days (d) after second graft
Mouse d 20 d 40 d 60 d 14 d 20 d 40 d 120 d 160
1 0 0 0 80 320 320 5120 640
2 0 0 0 0 0 0 160 0
3 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0
5 0 0 0 320 320 320 0 0
Titers of anti-BM IgG in hamster IgG-treated mice (controls)
1 2560 5120 5120 5120 5120 5120 5120 5120
2 640 640 1280 2560 5120 5120 5120 5120
BM, basement membrane; CD40L, CD40 ligand; IgG, immunoglobulin G;
Tg, transgene/transgenic; Wt, wild type.
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Figure 3. Lymphocytes from MR1-treated mice diminished or blocked anti-
BM IgG production by naive lymphocytes following cotransfer to Rag2/
mice (a) Adoptive transfer of 2107 lymphocytes from naive Wt mice to
Rag2/ mice endowed the latter (n¼ 5, circles) with the ability to develop
high and durable titers of anti-BM IgG following placement of hBPAG2 Tg
skin grafts; Tg skin grafts were lost in all mice within 10–20 days of the
appearance of such IgG. In contrast, when Rag2/ mice received 2 107
lymphocytes from MR1-treated mice mixed with an equivalent number of
lymphocytes from naive, Wt mice, they were hypo- or nonresponsive to a
subsequent hBPAG2 Tg skin graft (n¼ 4, triangles represent individual
animals). Only one such Rag2/ mouse lost its graft (again, soon after
developing high titers of anti-BM IgG [*]). (b) Rag2/ mice (n¼2) that
received 5 106 CD4þ T cells from MR1-treated mice mixed with 2107
naive Wt lymphocytes showed either low and transient, or greatly delayed
anti-BM IgG production following placement of Tg skin grafts (triangles
represent separate mice; controls represent the same shown in Figure 3a).
Again, the one mouse in this set that developed high titers of anti-BM IgG
(*, day 80), lost its graft within the subsequent 25 days. The dominant
tolerogenic effect of CD4þ T cells from MR1-treated mice appeared to be
dose dependent in that 2 107 of such CD4þ cells completely blocked anti-
BM IgG production by an equal number of Wt lymphocytes in Rag2/ mice
grafted with Tg skin (n¼ 2, small diamonds represent separate mice with
identical results).
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mice grafted with Tg skin. Interestingly, when Rag2/ mice
(n¼4) received a mixture of 2 107 lymphocytes from MR1-
treated mice and an equivalent number of lymphocytes from
naive, Wt mice, they were rendered hyporesponsive to
hBPAG2 Tg skin grafts. More specifically, one mouse in this
series failed to develop anti-hBPAG2 IgG, whereas three
others showed minimal and/or delayed development of
specific antibody (Figure 3a). Moreover, the only mouse in
this series that lost its graft did so after eventually developing
the highest titer of anti-BM IgG (titer, 2560). All other mice in
this series showed relatively low and transient levels of
hBPAG2-specific IgG and accepted skin grafts for the entire
period of study (that is, as long as 235 days).
In an analogous set of adoptive transfer experiments,
CD4þ T cells from MR1-treated Wt mice were mixed
with lymphocytes from naive, Wt mice and transferred to
Rag2/ mice that were then grafted with hBPAG2 Tg skin.
These studies found that 5 106 CD4þ T cells from MR-1
treated mice delayed or averted the immune responses of
cotransferred 2107 naive, Wt lymphocytes to hBPAG2 Tg
skin. Again, the only mouse in this experiment that lost its Tg
skin graft did so within 25 days of developing a relatively high
titer of anti-BM IgG on day 80 (titer, 5120). (Figure 3b). Anti-
BM IgG did not develop in Rag2/ Tg graft recipients that
had been similarly reconstituted with a mix of 2107 CD4þ
T cells from MR1-treated mice and an equal number of naive,
Wt splenocytes (Figure 3b). These experiments demonstrated
that CD4þ T cells from mice that were tolerant to hBPAG2
could transfer such hyporesponsiveness to other mice and
that this effect appeared to be dose dependent. Of note,
1.8–2.0 107 B cells from MR1-treated mice did not diminish
immune responses to hBPAG2 by 2 107 cotransferred,
naive, Wt lymphocytes in Rag2/ graft recipients (n¼ 5)
(data not shown).
DISCUSSION
The demonstration that Tg skin grafts elicited hBPAG2-
specific IgG (and graft loss) in Wt but not CD40L/
recipients illustrates the importance of CD40L signaling in the
generation of experimental immune responses in this defined
animal model. This conclusion was substantiated by the
demonstration that CD40L blockade with MR1mAb consis-
tently prevented specific IgG production in this model.
Transient MR1 administration not only blocked anti-BM IgG
production, but also fostered long-term acceptance of Tg skin
grafts and rendered such mice nonresponsive to a second
hBPAG2 Tg skin graft. As CD40L blockade by monotherapy
has been perceived to inhibit humoral-based diseases only
(Ferrant et al., 2004), the efficacy of this intervention supports
the premise that graft loss in this model is antibody mediated.
Of note, anti-CD40L monotherapy has not been successful in
controlling allograft rejection by CD8þ (Honey et al., 1999)
or CD4þ effector T cells (Jarvinen et al., 2003).
MR1 treatment is thought to block the initiation of
humoral immune responses as the expression of CD40L is
tightly regulated and because it is only transiently expressed
on activated T cells (that is, 1–2 hours after activation, peak
expression at 6–8 hours, rapid disappearance thereafter) (van
Kooten and Banchereau, 2000). In contrast, CD40:CD40L
blockade does not interfere with established humoral
immune responses exerted by long-lived CD40:CD40L
independent, antibody-secreting plasma cells. In accord with
these earlier observations, our studies found that MR1
administration did not reduce serum Ig levels or lower
established titers of hBPAG2-specific IgG in immune Wt
mice. These findings suggest that CD40L blockade may have
utility for prevention of unwanted humoral immune re-
sponses to hBPAG2 in generalized atrophic benign epider-
molysis bullosa patients undergoing gene replacement
therapy without causing systemic immunosuppression, but
not abrogate established autoimmune responses in patients
with bullous pemphigoid. Our studies highlight the complex-
ities of immunomodulatory effects resulting from transient
CD40L blockade. They also suggest that an active immune
regulatory mechanism may underlie tolerance to hBPAG2 in
MR1-treated mice and account for the dominant and
tolerogenic responses observed in our adoptive transfer
studies. Interestingly, this tolerance appeared to be mediated
by CD4þ T cells that exerted a dominant effect over larger
numbers of cotransferred naive Wt lymphocytes.
Our results are in accord with those developed in
analogous murine animal models exploring experimental
immune responses to Dsg3. MR1 (but not hIgG, control)
administration delayed and/or abrogated development of
anti-Dsg3 IgG in Dsg3/ mice grafted with Wt skin that
expressed this desmosomal cadherin (Ohyama et al., 2003).
Similarly, CD40:CD40L blockade inhibited production of
anti-Dsg3 IgG in Dsg3-positive Rag2/ mice carrying
lymphocytes from Dsg3/ mice (Aoki-Ota et al., 2006).
Hence, studies in two separate experimental animal models
indicate that CD40:CD40L signaling is important in the
generation of humoral immune responses to target antigens in
skin in vivo.
MATERIALS AND METHODS
Mice
The following strains of mice were used in these studies: C57BL/6 Tg
mice expressing hBPAG2 in murine epidermal BM (Olasz et al.,
2007); C57BL/6 Wt and CD40L/ mice (Jackson Laboratory, Bar
Harbor, ME); Rag2/ mice (Taconic Farms, Germantown, NY).
Mice were housed under sterile conditions in the Biomedical
Resource Center at the Medical College of Wisconsin and were
typically used between 6 and 12 weeks of age. All studies in animals
were approved by the Medical College of Wisconsin’s Animal Care
and Use Committee.
Skin grafting studies
Tail skin was harvested from hBPAG2 Tg mice and grafted onto the
backs of age- and gender-matched Wt, CD40L/, and Rag2/
recipients on day 0 as described previously (Rosenberg and Singer,
1988; Olasz et al., 2007). In sequential graft experiments, five MR1-
treated Wt mice (all seronegative for anti-hBPAG2 IgG and retaining
initial Tg skin grafts) received a second Tg skin graft on their alternate
flanks on day 60. Bandages were removed 7 days post-surgery and
grafts were evaluated for viability and size twice weekly. Grafts were
said to be lost if they became 20% or less of their original size.
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MR1/hIgG treatment regimen
Wt mice were grafted with Tg skin and injected i.p. with 1mg
hamster anti-CD40L MR1 mAb (Taconic Farms) or an equivalent
amount of control hIgG (Cappel Products, Aurora, OH) on day 0 and
with 0.5mg of these respective reagents on days 2, 4, 7, and 14.
Adoptive transfer studies
A total of 2 107 lymphocytes from lymph nodes and spleens of
MR1-treated Wt mice bearing intact and viable hBPAG2 Tg skin
grafts for 60 days were mixed with a equal number of lymphocytes
from naive, Wt mice and adoptively transferred to Rag2/ mice. In
an analogous set of experiments, 5–20 106 CD4þ T cells (purity
490% by flow cytometry; CD4 subset column kit; R&D Systems,
Minneapolis, MN) from MR1-treated Tg graft recipients were
cotransferred with 2 107 lymphocytes from naive Wt mice to
Rag2/ mice. As controls, Rag2/ mice were constituted
with 2 107 lymphocytes from naive Wt mice alone. These set of
Rag2/ mice were subsequently grafted with Tg skin and followed
for anti-BM IgG production and graft survival.
Indirect immunofluorescence microscopy
Serial dilutions of sera from mice grafted with hBPAG2 Tg skin were
tested for anti-BM IgG by indirect immunofluorescence microscopy
studies of 1 M NaCl split skin (Olasz et al., 2007).
Immunoblotting
IgG in murine sera were characterized for their reactivity to human
keratinocyte extracts as well as a bacterial recombinant correspond-
ing to the NC16A domain of hBPAG2 by immunoblotting (Olasz
et al., 2007). Sera from bullous pemphigoid patients and a murine
mAb directed against NC16A (HD-18) were used as positive
controls; normal mouse serum and normal human serum served as
negative controls.
Total IgG and IgM serum levels
Serum levels of murine IgG and IgM were quantitated with IgG or
IgM ELISA kits (Bethyl Laboratories, Montgomery, TX).
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